Oramed Pharmaceuticals (ORMP) EBT Margin (2016 - 2025)

Oramed Pharmaceuticals has reported EBT Margin for 8 years, with the latest figure at 352.9% in Q1 2025.

• For the quarter ending Q1 2025, EBT Margin changed N/A year-over-year to 352.9%; the trailing twelve-month figure through Dec 2025 stood at 3766.2% (changed N/A YoY), and the FY2025 full-year result was 3766.2%, changed N/A from the prior year.
• EBT Margin for Q1 2025 stood at 352.9%, down from 194.81% in the prior quarter.
• The five-year high for EBT Margin was 194.81% in Q2 2023, with the low at 1693.92% in Q2 2022.
• Historically, EBT Margin has averaged 996.01% across 4 years, with a median of 949.66% in 2021.
• The largest YoY upside for EBT Margin was 149911 bps in 2023 against a maximum downside of 90751 bps in 2023.
• Oramed Pharmaceuticals' EBT Margin stood at 850.5% in 2021, then plunged by 59 bps to 1355.64% in 2022, then surged by 86 bps to 194.81% in 2023, then sank by 81 bps to 352.9% in 2025.
• The last three EBT Margin figures came in at 352.9% (Q1 2025), 194.81% (Q2 2023), and 781.98% (Q1 2023), per Business Quant data.